Plectin-1 Targeted AAV Vector for the Molecular Imaging of Pancreatic Cancer by Prasad R. Konkalmatt et al.
ORIGINAL RESEARCH ARTICLE
published: 18 April 2013
doi: 10.3389/fonc.2013.00084
Plectin-1 targeted AAV vector for the molecular imaging of
pancreatic cancer
Prasad R. Konkalmatt 1, Defeng Deng2, StephanieThomas1, MichaelT.Wu1, Craig D. Logsdon2, Brent A.
French1,3,4,5 and Kimberly A. Kelly 1,5*
1 Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA
2 Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 Department of Medicine, University of Virginia, Charlottesville, VA, USA
4 Department of Radiology, University of Virginia, Charlottesville, VA, USA
5 Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA
Edited by:
Ruggero De Maria, Istituto Superiore
di Sanità, Italy
Reviewed by:
Paul B. Fisher, Virginia
Commonwealth University, School of
Medicine, USA
Junfang Ji, National Cancer Institute,
USA
*Correspondence:
Kimberly A. Kelly , Department of
Biomedical Engineering, University of
Virginia, UVA Health System Box
801394, Charlottesville, VA 22908,
USA.
e-mail: kak3x@virginia.edu
Pancreatic ductal adenocarcinoma (PDAC) is highly malignant disease that is the fourth
leading cause of cancer-related death in the US. Gene therapy using AAV vectors to selec-
tively deliver genes to PDAC cells is an attractive treatment option for pancreatic cancer.
However, most AAV serotypes display a broad spectrum of tissue tropism and none of the
existing serotypes specifically target PDAC cells.This study tests the hypothesis that AAV2
can be genetically re-engineered to specifically target PDAC cells by modifying the capsid
surface to display a peptide that has previously been shown to bind plectin-1. Toward this
end, a Plectin-1 Targeting Peptide (PTP) was inserted into the loop IV region of the AAV2
capsid, and the resulting capsid (AAV-PTP) was used in a series of in vitro and in vivo
experiments. In vitro, AAV-PTP was found to target all five human PDAC cell lines tested
(PANC-1, MIA PaCa-2, HPAC, MPanc-96, and BxPC-3) preferentially over two non-neoplastic
human pancreatic cell lines (human pancreatic ductal epithelial and human pancreatic stel-
late cells). In vivo, mice bearing subcutaneous tumor xenografts were generated using
the PANC-1 cell line. Once tumors reached a size of ∼1–2 mm in diameter, the mice were
injected intravenously with luciferase reporter vectors packaged in the either AAV-PTP or
wild type AAV2 capsids. Luciferase expression was then monitored by bioluminescence
imaging on days 3, 7, and 14 after vector injection. The results indicate that the AAV-PTP
capsid displays a 37-fold preference for PANC-1 tumor xenographs over liver and other
tissues; whereas the wild type AAV2 capsid displays a complementary preference for liver
over tumors and other tissues. Together, these results establish proof-of-principle for the
ability of PTP-modified AAV capsids to selectively target gene delivery to PDAC cells in vivo,
which opens promising new avenues for the early detection, diagnosis, and treatment of
pancreatic cancer.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related death in the United States. PDAC shows a
rapid clinical course, with a median survival of 6 months and a 5-
year survival rate of only 3% (Geer and Brennan, 1993; Hezel et al.,
2006). The high mortality rate in PDAC patients is linked to the
nature of underlying tumor biology. PDAC is highly malignant,
metastasizes extensively, and has late onset of clinical symptoms.
As pancreatic cancer is highly resistant to chemotherapy and radio-
therapy, the only potential cure currently available is complete
surgical resection of the tumor. However, surgery is possible only
in 10–20% of the patients due to extensive invasion of surrounding
structures at the time of diagnosis. Furthermore, complete resec-
tion of the primary as well as secondary tumors is rarely achieved
(Hezel et al., 2006). Therefore, novel and more effective treatments
are needed to improve the survival of pancreatic cancer patients.
Targeted gene therapy using an AAV vector designed to selectively
deliver therapeutic genes is an attractive and efficient option to
treat pancreatic cancer.
With rapid advances in the understanding of vector biology,
improved production of high titer stocks, and the discovery of
highly efficient new serotypes,AAV vectors have become one of the
most promising gene delivery systems currently available. Recom-
binant AAV vectors transduce a wide variety of tissues in vivo.
Engineered AAV vectors typically do not integrate into the host
genome, but rather exist as relatively stable episomes that are able
to provide long-term gene expression. Importantly, AAV vectors
provoke minimal immune responses in the host and are almost
entirely non-cytotoxic (Hernandez et al., 1999). However, the abil-
ity to transduce a wide range of tissues can be a disadvantage when
the objective is to target specific cell types for in vivo gene therapy.
These considerations emphasize the need for the development of
AAV vectors that can be used to target specific cells and tissues,
even after systemic (intravenous) administration.
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In order to render AAV vectors tissue-specific, one can use
genetic engineering techniques to express a ligand on the surface
of the viral capsid that recognizes a receptor specifically expressed
in the target tissue. This alteration is able to change the promis-
cuous tropism of the wild type AAV to a vector with a singular
specificity (Girod et al., 1999; Grifman et al., 2001; Nicklin et al.,
2001, 2003; Reynolds et al., 2001; Work et al., 2004). Like other
viruses, AAV infects cells by attaching to specific cell surface recep-
tors. In the case of AAV2, heparan sulfate proteoglycan (HSPG)
serves as a primary receptor (Summerford and Samulski, 1998;
Walters et al., 2004) while FGFR1 (Qing et al., 1999) and αvβ5
integrin (Summerford et al., 1999) serve as co-receptors. The
broad tropism of AAV2 is due to the fact that HSPG is present
on a wide variety of cell types. Further, mutational analyses of
the AAV capsid (cap) proteins have mapped the HSPG binding
sites to two regions: between amino acids 509–522 and 561–591
(Wu et al., 2000; Kern et al., 2003). Sequence alignment of AAV
with canine parvovirus for which the crystal structure is known,
predicted that these two regions form loop III and loop IV of a
beta barrel structure (Girod et al., 1999; Grifman et al., 2001).
By replacing the loop IV region of AAV structural protein with
specific targeting peptides, AAV vectors were constructed that tar-
get a number of cell types that were otherwise not permissive
for AAV2, including: mouse melanoma cells (Girod et al., 1999),
Kaposi sarcoma and rhabdomyosarcoma (Grifman et al., 2001),
and HUVECs (Nicklin et al., 2003; Work et al., 2006). These results
demonstrate that it is possible to develop AAV vectors targeted to
specific receptors of choice for use in gene therapy experiments
in vivo.
A critical step in developing receptor-targeted vectors is iden-
tifying a unique peptide ligand that specifically binds to the target
tissue when inserted into the context of the AAV capsid. The
choice of ligand to insert into the AAV capsid for the develop-
ment of a receptor-targeted vector relies on identifying biological
peptides with affinity for the specific cell/tissue type of interest.
Several groups have applied phage display technology to select
targeting peptides out of combinatorial libraries, and have spliced
these peptides into the AAV capsid to successfully transduce tar-
get cells that were otherwise not permissive for AAV (Girod et al.,
1999; Grifman et al., 2001; Nicklin et al., 2001). Recently, Kelly
et al. (2008), used phage display on early passage PDAC cell lines
isolated from relevant mouse models to identify peptides that
distinguish both human and murine PDAC cells from normal
pancreatic ductal cells in vitro and in vivo. Their study showed
that a bacteriophage clone displaying peptide 27 (Plectin-1 Tar-
geting Peptide, PTP) was highly specific for human PDAC cells.
Further, its target: Plectin-1 (Plec1) was subsequently found to
be expressed on all PDAC specimens examined (Bausch et al.,
2011).
Based on these observations, we hypothesized that an AAV2
capsid bearing PTP inserted into the loop IV region would tar-
get it to PDAC cells in vivo following systemic administration.
In the present study, as proof-of-principle we demonstrate that
the genetically modified AAV2 vector bearing PTP peptide pref-
erentially recognized PDAC cells in vitro and in vivo provided
targeted gene delivery in nude mice bearing pancreatic tumor
xenografts.
MATERIALS AND METHODS
PLASMIDS AND AAV VECTORS
The ITR-flanked recombinant AAV2 genome expressing fire-
fly luciferase under the control of the CMV promoter (pAAV-
CIL) was derived from pCMV-MCS (Agilent Technologies, Santa
Clara, CA, USA) by directionally subcloning the firefly luciferase
cDNA (Promega Corp., Madison, WI, USA) between the ClaI
and XbaI sites located downstream of the CMV promoter. The
rep/cap plasmid pAAV-PTP was constructed using plasmid pXX2-
∆LoopIV (a gift from Dr. Mathew D. Weitzman, Salk Institute,
San Diego, CA, USA). Plasmid pXX2-∆LoopIV contains AAV
rep and cap ORFs with unique MluI and SpeI sites at the loop
IV region of the AAV capsid protein designed to allow for the
in-frame insertion of peptide-encoding oligonucleotides (Grif-
man et al., 2001). A synthetic double-stranded oligonucleotide
(5′-cgcgtaaaaccctgctgccgaccccga-3′) encoding the heptapeptide
KTLLPTP with MluI and SpeI restriction sites at the 5′- and 3′-
ends, respectively, was inserted between the MluI and SpeI sites
of pXX2-∆LoopIV as indicated in Table 1. The construction of
the plasmid used to generate the reporter vector ACMVLuc has
been described previously (Prasad et al., 2011). The AAV plasmid
pAAV-sc-CBeGFP harboring a self-complementary AAV genome
expressing enhanced green fluorescent protein (eGFP) from the
chicken beta-actin promoter was obtained from the Penn Vector
Core (Philadelphia, PA, USA). AAV2 viruses were packaged by
double transfection and AAV-PTP viruses were packaged by the
triple transfection method in 293 cells. Titers for the AAV vec-
tors (viral genomes/ml; vg/ml) were determined by quantitative
real-time PCR as described previously (Prasad et al., 2011).
CELL LINES
Human pancreatic cancer (PDAC) cell lines (PANC-1, MIA PaCa-
2, HPAC, MPanc-96, and BxPC-3) were purchased from ATCC.
The immortalized human pancreatic ductal epithelial (HPDE)
cell line was a kind gift from Dr. Ming-Sound Tsao (University
of Toronto, Toronto, ON, Canada). Immortalized human pan-
creatic stellate cells (hPSC) were developed at the MD Anderson
Cancer Center and have been described previously (Hwang et al.,
2008). PDAC cells, 293-T and hPSC cell lines were maintained in
10% FBS/DMEM at 37˚C in a humidified atmosphere of 5% CO2.
HPDE cells were maintained in a specialized growth medium com-
posed of keratinocyte serum free medium supplemented with EGF
and bovine pituitary extract (Liu et al., 1998).
IN VITRO BIOLUMINESCENCE IMAGING
All cells were trypsinized (0.05% TE) and plated into 24-well
plates at a density of ∼50,000 cell/well. Upon reaching ∼50–60%
Table 1 | Amino acid sequence alignment of wild type AAV2,
AAV2∆LoopIV, and AAV-PTP capsids in the region spanning loop IV.
Wild type AAV2 TEQYGSVSTNLQRGNR–QAATADVNTQGVLPGMVWQ
AAV2∆LoopIV TEQYGSVSTNLQTR———-DITSDVNTQGVLPGMVWQ
AAV-PTP TEQYGSVSTNLQTRKTLLPTPTSDVNTQGVLPGMVWQ
The insertion of the Plectin-1 Targeting Peptide (PTP) is indicated in bold
characters.
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confluence, the cells were transfected with virus-containing
medium at a dose of 2.5× 104 vg/cell, in sets of four to eight
wells with either blank control (vehicle), or the CMV-driven
luciferase reporter vector (pAAV-CIL) packaged in the AAV2,
AAV2∆LoopIV, or AAV-PTP capsids. Before imaging at 24–48 h
after transfection, the transfection medium was replaced with new
medium containing d-luciferin (Caliper Life Sciences, Hopkin-
ton, MA, USA) at a concentration of 150µg/ml, and imaged using
the IVIS Spectrum system (Caliper Life Sciences) with an expo-
sure time of 1 min. Image data were quantified using Living Image
software (Caliper Life Sciences) and are presented as the ratio of
AAV-PTP to AAV2∆LoopIV after background subtraction.
MOUSE MODEL AND VECTOR ADMINISTRATION
Male athymic nude mice at age 7–9 weeks were purchased
from NCI (Frederick, MD, USA) and maintained on a 12/12 h
light/dark cycle at 24˚C and 60% humidity. Mice were injected
subcutaneously twice with 1× 106 PANC-1 cells bilaterally on
the back adjacent to shoulder blades. Tumors were allowed to
grow for 4 weeks until tumor size reached 1–2 mm in diam-
eter, at which time AAV vectors containing identical reporter
genomes (ACMVLuc) packaged in two different capsids (AAV2
or AAV-PTP) were administered. Three of the tumor-bearing
mice received the AAV2 vector and four received the AAV-PTP
vector. For IV injection, mice were anesthetized with 1–1.2%
isoflurane in oxygen. Viral solutions containing 1× 1012 vg/mouse
in 50–100µl of PBS were slowly injected via the jugular vein.
All work was performed according to animal protocols approved
by the Institutional Animal Care and Use Committee and con-
formed to the Guide for the Care and Use of Laboratory
Animals.
IN VIVO BIOLUMINESCENCE IMAGING
Luciferase expression in live mice was non-invasively assessed
by in vivo bioluminescence imaging using previously reported
methods (Wu et al., 2002; Prasad et al., 2007). Animals were
anesthetized and maintained on 1–1.2% isoflurane in oxygen.
d-luciferin (150µg/g body weight, Caliper Life Sciences) was
administered to mice by intraperitoneal injection. Eight minutes
following d-luciferin administration, all mice were imaged using
an IVIS 100 imaging system (Caliper Life Sciences). Photons emit-
ted from the mice were collected and integrated for a period of
1 min. Images were processed using Living Image software (Caliper
Life Sciences).
LUCIFERASE ACTIVITY ASSAY
Luciferase activity in various organs was measured using reagents
from Promega Corp. (Madison, WI, USA). Heart, liver, lung, kid-
ney, spleen,gastrocnemius muscle, and tumors were collected from
mice after bioluminescence imaging 14 days post vector injec-
tion. Protein extracts from the whole organs were prepared as
recommended by the manufacturer and protein concentrations
were determined using the Bio-Rad DC BCA protein assay kit.
Luciferase activity in the protein samples was determined using
a FLUOstar Optima micro-plate reader (BMG Labtech, Durham,
NC, USA) and expressed as relative light units per mg of protein
(RLU/mg protein).
IMMUNOHISTOCHEMISTRY
Enhanced green fluorescent protein expression in mouse
tumors was documented by immunohistochemistry as previously
described (Prasad et al., 2011). Two weeks following vector admin-
istration (1× 1012 vg/mouse), tumors were collected and fixed in
3.7% paraformaldehyde for 1 h at 4˚C. After washing in PBS (three
times, 5 min each), tumors were equilibrated with 30% sucrose in
PBS overnight and 6µm cryosections were prepared. The sections
were immunostained for eGFP using rabbit polyclonal anti-GFP
antibody (Abcam Inc, Cambridge, MA, USA).
STATISTICAL ANALYSIS
Student’s t -test was used to evaluate differences between experi-
mental and control groups with p< 0.05 considered significant.
All data are expressed as mean± standard error of the mean.
RESULTS
AAV-PTP PREFERENTIALLY TARGETS PANCREATIC CANCER CELL LINES
An in vitro analysis of AAV2 capsids displaying the PTP peptide
(AAV-PTP) was performed on five human pancreatic cancer lines
(PANC-1, MIA PaCa-2, HPAC, MPanc-96, and BxPC-3). For com-
parison, two non-neoplastic control cell lines were also included
consisting of immortalized HPDE cells and immortalized hPSC.
The AAV viruses all contained the same CMV-driven luciferase
reporter genome packaged into three different capsids (AAV2,
AAV2∆LoopIV, or AAV-PTP). The primary virus stocks were
titered and applied to the PDAC cell lines and non-neoplastic con-
trol cell lines. Compared to the control capsid (AAV2∆LoopIV),
the pancreatic cancer-targeted capsid (AAV-PTP) was 4, 13, 6, 4,
and 30 times more efficient at the transduction of PDAC cell lines
PANC-1, MiaPaCa2, HPAC, MPanc-96, and BxPC-3, respectively;
than it was at transducing the non-neoplastic cell lines (HPDE and
hPSC, Figure 1). However, this increase in selectivity was associ-
ated with a modest loss in overall gene transfer efficiency, since the
absolute levels of light production from AAV2 in the neoplastic
human cell lines was approximately 4.4-fold higher than AAV-
PTP in those same neoplastic cells (data not shown). These results
show that the AAV2 vector bearing the PTP peptide preferentially
transduces and expresses recombinant genes in human PDAC cell
lines over non-neoplastic human pancreatic cell lines, albeit with
some loss in overall efficiency relative to AAV2.
AAV-PTP SELECTIVELY DELIVERS GENES TO PANCREATIC TUMORS
In order to test whether the AAV-PTP vector could deliver genes
selectively to pancreatic tumors in vivo, we used PANC-1 cells to
generate mice bearing subcutaneous tumor xenografts. When the
tumors reached a size of ∼1–2 mm in diameter (∼4 weeks after
inoculation), the mice were injected with AAV-PTP or wild type
AAV2 capsids containing identical vector genomes that express
luciferase from the CMV promoter. Luciferase expression was
monitored by in vivo bioluminescence imaging on day 3, 7, and 14
after vector injection. At every time point tested, luciferase expres-
sion was predominantly found around the abdominal cavity in
mice injected with wild type AAV2 (Figure 2A, left). However, in
mice injected with the AAV-PTP capsid, luciferase expression was
found predominantly in the tumors (Figure 2A, right) with only
minimal expression in non-tumor regions.
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FIGURE 1 | AAV-PTP preferentially targets human PDAC cells over
non-PDAC cells in vitro. Two non-neoplastic human cell lines: HPDE
(immortalized human pancreatic ductal epithelial cells) and hPSC
(immortalized human pancreatic stellate cells) and five human pancreatic
cancer cell lines (PANC-1, MIA PaCa-2, HPAC, MPanc-96, and BxPC-3) were
either mock-transfected or transfected with identical reporter genomes
packaged in the AAV2 capsid, negative control capsid (AAV2∆LoopIV), or
the plectin-1 targeted capsid (AAV-PTP). Luciferase signals were imaged
using an IVIS Spectrum and quantified using Living Image software. The
results in the graph are presented as the ratio of AAV-PTP to AAV2∆LoopIV
after background subtraction. Asterisks (*) denote p<0.05 vs. the mean of
the two non-neoplastic control cell lines (HPDE and hPSC).
To confirm selective gene delivery to the tumors by AAV-PTP,
a panel of organs was collected 14 days following vector injec-
tion and luciferase activity was measured in the protein extracts.
Luciferase assays on protein extracts showed that in mice injected
with wild type AAV2 capsids, luciferase activity was predominantly
present in the liver as compared to other organs (Figure 2B). On
the other hand, in mice injected with AAV-PTP capsids, luciferase
activity was 37-fold higher in the tumors as compared to that
in liver. Transduction of tumor cells was 24-fold higher with
AAV-PTP than with wild type AAV2 capsids. Only low levels of
transduction were noted with either wild type AAV2 or AAV-PTP
capsids in other organs (heart, lung, kidney, spleen, and skeletal
muscle). These results indicate that AAV2 capsids bearing the PTP
peptide selectively deliver genes to pancreatic cancer cells in mice
bearing pancreatic tumor xenografts.
To test the distribution of gene expression within tumor
xenografts, we used an scAAV vector harboring eGFP cDNA under
the control of the chicken β-actin promoter (pAAV-sc-CBeGFP).
We injected 1× 1012 vg/mouse of either AAV2 or AAV-PTP capsids
carrying the AAV-sc-CBeGFP genome into mice bearing PANC-1
xenografts. Two weeks following vector injection, tumors were
collected and eGFP expression was detected by immunohisto-
chemical analysis. Results indicated that eGFP expression was
evenly distributed throughout the tumor (Figure 3).
DISCUSSION
Our results demonstrate that replacing the loop IV region of the
AAV2 capsid with a peptide that recognizes plectin-1 facilitates
selective gene delivery to PDAC cells. This is the first demon-
stration of a viral vector with pancreatic cancer cell specificity.
FIGURE 2 | AAV-PTP selectively targets PDAC tumors in vivo. (A)
Bioluminescence imaging of mice bearing PANC-1 tumor xenografts. Nude
mice bearing PANC-1 tumor xenografts (seven total) were injected
intravenously with a single dose (1×1012 vg per mouse) of AAV2 (n= 3) or
AAV-PTP (n= 4) carrying the ACMVLuc reporter vector genome. Following
vector administration, luciferase expression was monitored on days 3, 7,
and 14 post-injection by non-invasive in vivo bioluminescence imaging.
Bioluminescence images acquired on day 14 following vector administration
are shown. White circles show the sites of tumor cell injections. (B)
Luciferase activity assay showing tumor-targeted gene delivery. Two weeks
following vector administration, the mice described above were euthanized
and a panel of tissues (Liver, Heart, Lung, Kidney, Spleen, Skeletal (Sk.)
muscle, and Tumor) was collected for quantitative luciferase
determinations. Luciferase assays were performed using the in vitro
luciferase assay kit (Promega Corporation) on protein extracts prepared as
per manufacturer’s guidelines. Luciferase activities are reported as relative
light units per mg tissue (RLUs/mg tissue). Asterisks (*) denote p<0.05 vs.
any other tissue harvested from the same group (AAV2 or AAV-PTP).
The Plectin-1 Targeted Peptide (PTP) modified AAV2 capsid was
shown to localize to tumor xenografts in mice indicating that the
natural tropism of the AAV2 capsid for hepatocytes was dramati-
cally altered. Replacing the loop IV region of AAV2 with PTP did
not adversely affect the generation of viral capsids, as evidenced
by titers comparable to wild type AAV2. We routinely generated
recombinant vectors with titers exceeding 5× 1012 vg/ml, indicat-
ing that the insertion of the PTP heptapeptide was well tolerated
for efficient packaging of viral particles.
In vitro experiments comparing neoplastic and non-neoplastic
cell lines showed that AAV-PTP preferentially transduced all 5
PDAC cell lines tested (PANC-1, MIA PaCa-2, HPAC, MPanc-96,
and BxPC-3), but did not efficiently transduce two non-neoplastic
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FIGURE 3 | Distribution of AAV-PTP targeted PANC-1 cells in tumor
xenografts. Immunohistochemistry for eGFP was performed on tumor
sections to characterize the distribution of targeted gene delivery. Nude
mice bearing PANC-1 tumor xenografts were injected intravenously with a
single dose of AAV-PTP capsid carrying the sc-CBeGFP reporter vector
genome (1×1012 vg per mouse). Two weeks following vector
administration, cryosections of tumors were prepared and processed for
eGFP detection by immunohistochemistry. PANC-1 cells expressing eGFP
were stained golden-brown in color by the chromogen substrate
(diaminobenzidine).
pancreatic cell types (HPDEs and hPSCs, see Figure 1). Besides
providing a foundation for PDAC imaging and neoplasia-targeted
suicide gene therapy, this differential in transduction efficiency
may prove valuable in basic science studies aimed at dissecting
out the relative contributions of neoplastic PDAC cells and non-
neoplastic pancreatic cells (e.g., pancreatic stellate cells) in the
formation of pancreatic tumors. The PTP peptide was identified
by phage display on primary pancreatic cancer cell lines and its
binding partner (plectin-1) was found on all primary and metas-
tasized PDAC specimens tested to date (17). Further, the absence
of plectin-1 on the plasma membranes of cells in most normal tis-
sues (17) further enhances the ability of PTP to selectively target
PDAC cells.
The in vitro studies were complemented by in vivo studies
undertaken to determine whether AAV-PTP can selectively deliver
genes to pancreatic tumor cells in mice as proof-of-principle and
as an initial step toward gene therapy. We choose plectin-1 posi-
tive PANC-1 cells to generate subcutaneous tumor xenografts in
mice. Mice bearing PANC-1 tumor xenografts were injected with
a luciferase reporter vector packaged in either wild type AAV2 or
AAV-PTP capsids. Bioluminescence imaging for luciferase expres-
sion showed that, in mice injected with wild type AAV2 capsids,
light output was detected in the abdominal cavity, whereas in
mice injected with AAV-PTP capsids, light output was detected
almost exclusively in the tumors (Figure 2A) with little or no
signal originating from the region of the healthy pancreas. These
results indicate that the wild type AAV2 capsid preferentially trans-
duced liver hepatocytes whereas the AAV-PTP capsid efficiently
transduced tumor cells. Luciferase activity assays performed on
protein extracts from various organs collected on day 14 post
vector injection demonstrated that luciferase activity in the liver
was highest in mice injected with wild type AAV2 capsids. In
contrast, in the mice injected with AAV-PTP, luciferase activity
was highest in the tumors compared to all other organs. These
results show that AAV-PTP capsids selectively transduce pancre-
atic cancer cells in mouse tumor xenografts with minimal gene
expression in other organs including liver following systemic
administration. Thus AAV vectors can successfully be modified
to deliver genes specifically to pancreatic cancer cells using the
cancer cell-specific property of cell surface localization of plectin-
1. With further refinements, this approach may hold promise
for the early detection, diagnosis and treatment of pancreatic
cancer.
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